Abstract: Provided are a composition, a method of treating a metal-containing layer by using the composition, and a method of manufacturing a semiconductor device by using the composition. The composition may include an oxidizing agent, an ammonium-containing compound, and an etching controller. The etching controller may include a compound represented by Formula 1. A description of Formula 1 is provided herein.

Abstract: An organometallic compound, represented by Formula 1: wherein, Ln1 is a ligand represented by Formula 1-1, Ln2 is a ligand represented by Formula 2-1 or 2-2, n1 is 1, 2, or 3, and n2 is 0, 1, or 2, wherein CY1 is a benzoquinoline group or a benzoisoquinoline group, X31 and X32 are each independently O or S; R10, R21 to R28, R31 to R37, R41 to R44, and b10 are as defined herein; and * and *? each indicate a binding site to M1.

Abstract: Provided are a composition, a method of treating a metal-containing layer by using the same, and/or a method of manufacturing a semiconductor device by using the same. The composition may include an oxidizing agent, an acid, and an etching controller, wherein the etching controller may include at least one compound represented by Formula 1: A description of Formula 1 is provided in the specification of the present application.

Abstract: An organometallic compound represented by Formula 1: M(L1)n1(L2)n2??Formula 1 wherein M is a transition metal, L1 is a ligand represented by Formula 2 as provided herein, n1 is 1, 2, or 3, wherein, when n1 is 2, two L1 groups are identical to or different from each other, and when n1 is 3, two or more of three L1 groups are different from each other, L2 is a monodentate ligand, a bidentate ligand, a tridentate ligand, or a tetradentate ligand, and n2 is 0, 1, 2, 3, or 4, wherein, when n2 is 2 or greater, two or more L2 groups are identical to or different from each other, and L1 and L2 are different from each other.

Abstract: An organometallic compound represented by Formula 1: M1(Ln1)n1(Ln2)n2??Formula 1 wherein M1 is a transition metal, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein ring CY4 is a polycyclic C5-C30 carbocyclic group or a polycyclic C1-C30 heterocyclic group; Y1 is O, S, or Se; Z1 is —Si(Q1) (Q2) (Q3) or —Ge(Q1) (Q2) (Q3); a1 is 1, 2, 3, or 4; at least one of R1 and R2 is a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C3-C10 cycloalkyl group, or a substituted or unsubstituted C6-C60 aryl group; and the remaining substituent groups are as defined herein.

Abstract: An organometallic compound represented by Formula 1: M1(Ln1)n1(Ln2)n2??Formula 1 wherein M1 is a transition metal; Ln1 is a ligand represented by Formula 1A; Ln2 is a ligand represented by Formula 1B; n1 is 1 or 2, and n2 is 1, 2, or 3: wherein X1 is O, S, or Se; ring CY1 is a C5-C30 carbocyclic group or a C1-C30 heterocyclic group; a1 is 0, 1, 2, or 3; Y1 and Y2 are each independently a C1-C60 alkyl group substituted with at least one deuterium, a C6-C60 aryl group substituted with at least one deuterium, or R33; at least one of Y1 and Y2 is a C1-C60 alkyl group substituted with at least one deuterium or a C6-C60 aryl group substituted with at least one deuterium; * and *? each indicate a binding site to M1; and the remaining substituent groups and variables are as defined herein.

Abstract: An organometallic compound represented by Formula 1: M1(L1)n1(L2)n2??Formula 1 wherein M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2, wherein X1 is C or N; X2 is C or N; X3 is C or N; and X4 is C or N; Y1 is O, S, or Se; R32 and R33 are each independently deuterium, a substituted C1-C60 alkyl group comprising deuterium, a substituted C3-C10 cycloalkyl group comprising deuterium, a substituted C6-C60 aryl group comprising deuterium, or a substituted C1-C60 heteroaryl group comprising deuterium, and the remaining substituent groups in Formulae 1A and 1B are each as described herein.

Abstract: An organometallic compound represented by Formula 1: M1(L1)n1(L2)n2??Formula 1 wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2, wherein X1 is C or N; X2 is C or N; X3 is C or N; X4 is C or N; ring CY1 and ring CY2 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group; Z1 and Z2 are each independently —Si(Q1)(Q2)(Q3) or —Ge(Q1)(Q2)(Q3); a1 and a2 are each independently an integer from 0 to 10; a sum of a1 and a2 is 1 or greater; and the remaining substituent groups are as described herein.

Abstract: An organometallic compound represented by Formula 1: M1(L1)n1(L2)n2??Formula 1 wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2, wherein X1 is C or N, X2 is C or N, at least one R2 is a C1-C10 alkyl group that is substituted with a fluorine, b1 is an integer from 1 to 6, b2 is an integer from 1 to 10, * and *? each indicate a binding site to M1, and the other substituent groups of Formulae 1A and 1B are as described herein.

Abstract: An organometallic compound represented by Formula 1: M1(L1)n1(L2)n2??Formula 1 wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2, wherein, X1 to X4 are each independently C or N, ring CY1 and ring CY2 are each independently a C6-C30 carbocyclic group or a C1-C30 heterocyclic group, Z1 and Z2 are each independently —Si(Q1)(Q2)(Q3) or —Ge(Q1)(Q2)(Q3), a1 and a2 are each independently an integer from 0 to 10, a sum of a1 and a2 is 1 or greater, Y1 is O, S, Se, C(R51)(R52), or N(R53), Y2 is O, S, Se, C(R61)(R62), or N(R63), * and *? each indicate a binding site to M1, and the other substituent groups are as described herein.

Abstract: An organometallic compound represented by Formula 1: M1(L1)n1(L2)n2??Formula 1 wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, n1 and n2 are each independently 1 or 2, Formula 1A Formula 1B wherein X1 to X4 are each independently C or N, rings CY1 and ring CY2 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, Z1 and Z2 are each independently Si(Q1)(Q2)(Q3) or —Ge(Q1)(Q2)(Q3), provided that each of Z1 and Z2 is not —SiH3, a1 and a2 are each independently an integer from 0 to 10, a sum of a1 and a2 is 1 or greater, Y1 and Y2 are each independently O, S, Se, or C(R5)(R6), * and *? each indicates a binding site to M1, and R1 to R3, R5, R6, and R41 to R48 are as described herein.

Abstract: Provided are a light-emitting device and an electronic apparatus including the light-emitting device, the light-emitting device including: a first electrode; a second electrode; an emission layer arranged between the first electrode and the second electrode; and a buffer layer arranged between the first electrode and the emission layer, wherein the buffer layer is in direct contact with the emission layer, the emission layer includes a first compound represented by Formula 1, and the buffer layer includes a second compound represented by Formula 5. The first compound and the second compound are respectively the same as those described in the present specification.

Abstract: An organometallic compound represented by Formula 1: wherein M1 is a transition metal, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein ring CY3 is: a 5-membered N-containing heterocyclic group; or a 5-membered N-containing heterocyclic group condensed with a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, ring CY4 is: a 6-membered carbocyclic group; a 6-membered heterocyclic group; a 6-membered carbocyclic group condensed with a C5-C30 carbocyclic group or a C1-C30 heterocyclic group; or a 6-membered heterocyclic group condensed with a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, Y1 is O, S, Se, or C(R1)(R2), Y2 is O or S, and b30, b40, R1, R2, R11 to R14, R21 to R26, R30, and R40 are as defined herein.

Abstract: An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2??Formula 1 wherein, in Formula 1, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein X1, X2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, CY1, CY2, CY3, T1, T2, a1, a2, R10, R20, R30, b10, b20, and b30 are each as described herein.

Abstract: An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2??Formula 1 wherein, Ln1 is a ligand represented by Formula 1-1, Ln2 is a ligand represented by Formula 2-1 or 2-2, n1 is 1, 2, or 3, and n2 is 0, 1, or 2, wherein CY1 is a benzoquinoline group or a benzoisoquinoline group, X31 and X32 are each independently O or S; R10, R21 to R28, R31 to R37, R41 to R44, and b10 are as defined herein; and * and *? each indicate a binding site to M1.

Abstract: An organometallic compound represented by Formula 1: wherein Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, X1 is O, S, or Se, CY1 is a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, n1 is 1 or 2, n2 is 1, 2, or 3, and the remaining substituents are as defined in the present specification.

Abstract: An organometallic compound represented by Formula 1: M(L1)n1(L2)n2??Formula 1 wherein M is a transition metal, L1 is a ligand represented by Formula 2 as provided herein, n1 is 1, 2, or 3, wherein, when n1 is 2, two L1 groups are identical to or different from each other, and when n1 is 3, two or more of three L1 groups are different from each other, L2 is a monodentate ligand, a bidentate ligand, a tridentate ligand, or a tetradentate ligand, and n2 is 0, 1, 2, 3, or 4, wherein, when n2 is 2 or greater, two or more L2 groups are identical to or different from each other, and L1 and L2 are different from each other.